Clinical trial · Observational
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
NCT02143999CI-TRIAL-00028298completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation. Patients will be treated per the locally approved therapeutic options in clinical practice. The observation period for each patient will be up to 24 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Melanoma | Melanoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 2 years
Secondary outcomes (6)
- measure
- Progression-free survival
- timeFrame
- 2 years
- measure
- Best Overall Response Rate (BORR)
- timeFrame
- 2 years
- measure
- Time to response
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, \>/= 18 years of age at diagnosis * Histologically confirmed new diagnosis of unresectable or metastatic melanoma * Patients with tumor samples available for assessment of BRAF V600 mutation Exclusion Criteria: * Prior systemic therapy for metastatic disease * Participation in interventional clinical trials
References
Publications (0)
Data not yet available
No reference posted for this study.